PMID: 6412535Sep 1, 1983Paper

Hemodynamic effects of encainide in patients with ventricular arrhythmia and poor ventricular function

The American Journal of Cardiology
M SamiR Lisbona

Abstract

Gated cardiac scanning was used to evaluate the hemodynamic effects of encainide in 19 patients (1 woman) with complex ventricular arrhythmia and depressed left ventricular (LV) function (ejection fraction less than 45%). Patients were 36 to 80 years old (average 61). All were candidates for long-term encainide therapy after having failed with currently available antiarrhythmics. Sixty-three percent had congestive heart failure before they received encainide. All were evaluated in the hospital before encainide therapy by a gated cardiac scan performed at least 3 days after discontinuing all antiarrhythmic drugs. Patients received oral encainide in doses of 75 to 200 mg. Gated cardiac scans were repeated 1 to 2 weeks later when an 80% reduction in frequency of premature ventricular complexes was observed on a 24-hour Holter recording. No patient had worsening of congestive heart failure during encainide therapy. Encainide did not significantly affect ejection fraction, which averaged 22 +/- 10% before and 25 +/- 14% (SD) after encainide (difference not significant [NS]). Other hemodynamic variables, including heart rate, blood pressure, stroke volume and end-diastolic volume, remained unchanged during encainide therapy. Digoxin ...Continue Reading

References

May 31, 1979·The New England Journal of Medicine·W D HagerS Goldman
Sep 27, 1979·The New England Journal of Medicine·W S Kammerer
May 22, 1978·The American Journal of Cardiology·D P Zipes
Nov 1, 1972·American Heart Journal·K E HammermeisterJ R Warbasse
Dec 1, 1980·American Heart Journal·D C HarrisonJ Mason
Dec 1, 1980·American Heart Journal·D E Jewitt
Jul 1, 1981·The American Journal of Cardiology·M SamiR F DeBusk
Mar 13, 1980·The New England Journal of Medicine·P J PodridB Lown
Dec 1, 1980·Circulation·M SamiR F DeBusk

❮ Previous
Next ❯

Citations

Jun 1, 1990·Cardiovascular Drugs and Therapy·M Sami
Jun 1, 1990·Cardiovascular Drugs and Therapy·J A Thomis
Oct 1, 1989·Cardiovascular Drugs and Therapy·M J AntonaccioJ E Byrne
Aug 29, 1986·The American Journal of Cardiology·M H Sami
Jan 1, 1986·Journal of the American College of Cardiology·J MorganrothD M Salerno
Feb 1, 1987·Journal of the American College of Cardiology·L N Horowitz, J Morganroth
Feb 20, 1990·The American Journal of Cardiology·P J Podrid, S L Beau
Dec 5, 1989·The American Journal of Cardiology·P Jaillon, M Drici
Aug 29, 1986·The American Journal of Cardiology·J Morganroth
Aug 29, 1986·The American Journal of Cardiology·B D QuartA J Wood
Nov 1, 1989·American Heart Journal·S S Gottlieb
Jan 15, 1988·The American Journal of Cardiology·R L Woosley, C Funck-Brentano
Dec 20, 1988·The American Journal of Cardiology·P J MäkynenR K Liisanantti
Jan 31, 1986·The American Journal of Cardiology·R L WoosleyD M Roden
Aug 29, 1986·The American Journal of Cardiology·L F Soyka
Jul 1, 1991·Chest·W J GibbonsM G Cosio
Jun 1, 1986·Comprehensive Therapy·D Rupp, M Dunn
Oct 1, 1989·Pacing and Clinical Electrophysiology : PACE·R LemeryD Roy
Jul 1, 1988·Clinical Cardiology·E WeinhouseD B Nudel
Nov 1, 1990·Postgraduate Medicine·K A EllenbogenH Sheehan
Jan 1, 1986·Drug Intelligence & Clinical Pharmacy·A E Wehmeyer, R L Thomas
Apr 28, 1988·The New England Journal of Medicine·R L WoosleyD M Roden
May 1, 1989·Postgraduate Medicine·H SkluthJ Gums

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.